SRNE News and Press, Sorrento Therapeutics Inc. From 06/22/21

Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021. Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021. Studies are complementary and address both dose duration and disease stage variations. Data from b...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so much enthusiasm baked into the equities sector, many investors undoubtedly feel that now is a time to consider a risk-off profile. Frankly, I agree with these folks. That said, we’re coming off the (hopefully...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it may seem like “meme-stock mania” is over, several of these names are still up triple digits this year. In fact, much-maligned meme stocks are not losing steam as the more than 10 million members of R...

Sorrento Therapeutics (NASDAQ: SRNE) didn't have a case of the Mondays at all. The company's stock zoomed 6.7% higher today on very encouraging news from across the pond. After U.S. market hours on Friday, Sorrento divulged that the U.K.'s Medicines and Healthcare Products Regul...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sorrento Therapeutics (NASDAQ: SRNE ) is a stock that’s on fire today. Investors in SRNE stock have seen gains of 6% at the time of writing on heavy volume. More than double the average daily volume of shares h...

loops7/E+ via Getty Images Sorrento Therapeutics (SRNE) has risen ~3.5% in extended trading after announcing that the company received regulatory clearance in the U.K. to start a Phase 2 efficacy trial for its COVI-DROPS product candidate. The decision by the Medicines and...

Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients. COVI-DROPS is administered by intranasal drops and the antibody is active against the original SARS-CoV-2 virus, as well as the UK/Alpha and India/Delta variants, cur...

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology acro...

APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib. The data could be a catalyst event (up or down) for this stock. There's a lot of competition for non-covalent Btk inhibitors in blood cancers. For further details see: Aptose: Cancer Trial Catalyst A...

Photo by AlexanderFord/E+ via Getty Images Sorrento Therapeutics (SRNE) announced that HER2-ADC, A166 an experimental breast cancer therapy developed in partnership with Kelun-Biotech indicated a “better safety profile” and “potentially better efficacy” in a P...